Anti-relapse Efficacy and Tolerance Assessment of a Cosmetic Cream for Very Dry, Irritated to Atopic Sensitive Skin.

Inclusion Criteria:

• General criteria:

Healthy subject (except AD and other atopic diseases - allergic rhinitis, conjunctivitis, and asthma). The subject can keep its usual treatment (antihistamines, inhaled corticosteroids, and antileukotriene treatment) during the study if applicable. Written informed consent from the subject's parent(s)/legal representative(s) and children over 8 years old (specific Argentina) and over 12 years old (specific Singapore). Subject accepting to continue the normal conditions of hygiene and sunscreen (if applicable). Subject, parents/legal representative(s) willing to adhere to the study protocol and procedures.

Specific criteria:

Sex: male or female. Age: from 6 months to 15 years. Subject having on average one flare-up per month during the four months preceding the study, including the one observed on the inclusion visit D0. Subject having EASI value from 7.1 - 21 on D0 (moderate AD). Subject having one atopic eruption on the inclusion visit which the dermatologist will prescribe topical corticosteroids or calcineurin's inhibitors (pimecrolimus and/or tacrolimus).

Exclusion Criteria:

• Subject presenting cutaneous pathology in the studied zone other than AD (accordingto the investigator's appreciation, i.e., acne, psoriasis). Subject using systemictreatment, including oral steroids and oral immunosuppressants e.g., ciclosporinduring the previous weeks liable to interfere with the assessment of the cutaneoustolerance of the study product or placebo (according to the investigator'sappreciation). Subject using skin-moisturizing products from inclusion (D0) otherthan the study product or placebo. Subject who had systemic therapy withimmune-suppressive drugs and antibiotics within the last 14 days before thebeginning of the study Subject having serious illness that might require regularsystemic medication (e.g., insulin-dependent diabetes, cancer) or conditions thatexclude a participation or might influence the study evaluation. Subject withdocumented allergies to the study product or placebo ingredients. Subject enrolledin another clinical study during the study period. Parent(s)/legal representative(s)considered by the investigator to be likely not compliant to the protocol.